Taurine in health and diseases: consistent evidence from experimental and epidemiological studies.
Taurine (T) was first noted as beneficial for stroke and cardiovascular diseases (CVD) prevention in genetic rat models, stroke-prone spontaneously hypertensive rats (SHRSP). The preventive mechanisms of T were ascribed to sympathetic modulation for reducing blood pressure (BP) and anti-inflammatory action. Recent epidemiological surveys revealed the involvement of inflammatory mediators in the pathogenesis of stroke and also atherosclerosis for which T was proven to be effective experimentally. Arterio-lipidosis prone rats, a substrain of SHRSP selectively bred for higher reactive hypercholesterolemia, quickly develop not only arterial fat deposition but also fatty liver which could be attenuated by dietary T supplementation. CARDIAC (CVD and Alimentary Comparison) Study was a WHO-coordinated multi-center epidemiological survey on diets and CVD risks and mortalities in 61 populations. Twenty-four-hour urinary (24U) T was inversely related significantly with coronary heart disease mortality. Higher 24U-T excreters had significantly lower body mass index, systolic and diastolic BP, total cholesterol (T-Cho), and atherogenic index (AI: T-Cho/high density lipoprotein-cholesterol) than lower T excreters. T effects on CVD risks were intensified in individuals whose 24U-T and -magnesium (M) excretions were higher. Furthermore, higher Na excreters with higher heart rate whose BP were significantly higher than those with lower heart rate were divided into two groups by the mean of 24U-T, high and low T excreters. Since the former showed significantly lower BP than the latter, T may beneficially affect salt-sensitive BP rise. Included among the typical 61 populations, were Guiyang, China or St. John's, Newfoundland, Canada where in which the means of both 24U-T and -M were high or low, respectively. The former and the latter had low and high CVD risks, respectively. Australian Aboriginals living at the coastal area in Victoria were supposed to eat T- and M-rich bush and sea foods and be free from CVD 200 years ago, but they presently have nearly the highest CVD risks indicating that T- and/or M-containing seafood, vegetables, fruits, nuts, milk, etc, similar to prehistoric hunters' and gatherers' food should be good for CVD prevention. The preventive effects of T, good for health and longevity, first noted experimentally, were also proven epidemiologically in humans.
Yamori
Yukio
Y
Institute for World Health Development, Mukogawa Women's University, Nishinomiya 6638143, Japan. yamori@cardiacstudy.com
Taguchi
Takashi
T
Hamada
Atsumi
A
Kunimasa
Kazuhiro
K
Mori
Hideki
H
Mori
Mari
M
D000818:Animals; D001794:Blood Pressure / Q000502:physiology; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control; D002791:Cholesterol, Dietary / Q000009:adverse effects; D004032:Diet; D004041:Dietary Fats / Q000009:adverse effects; D006801:Humans; D006973:Hypertension; D008099:Liver / Q000473:pathology; D008274:Magnesium / Q000378:metabolism; D012306:Risk; D012307:Risk Factors; D020521:Stroke / Q000453:epidemiology / Q000517:prevention & control; D013654:Taurine / Q000378:metabolism / Q000627:therapeutic use*
D002791:Cholesterol, Dietary; D004041:Dietary Fats; D013654:Taurine; D008274:Magnesium
Mol Aspects Med. 2003 Feb-Jun;24(1-3):107-36
12537992
Exp Clin Cardiol. 2006 Summer;11(2):94-8
18651042
Adv Exp Med Biol. 1996;403:623-9
8915403
J Nutr. 1999 Sep;129(9):1705-12
10460208
Life Sci. 1996;58(19):1643-51
8632701
Eur J Pharmacol. 2008 Nov 12;597(1-3):75-80
18796303
J Clin Biochem Nutr. 2009 Jul;45(1):37-43
19590705
Am J Hypertens. 2009 Oct;22(10):1070-5
19617879
Physiol Rev. 1992 Jan;72(1):101-63
1731369
Jpn Circ J. 1975 May;39(5):601-9
1152192
Stroke. 1976 Mar-Apr;7(2):120-5
1265803
Int J Cardiol. 2010 Nov 5;145(1):73-4
19446895
J Hypertens. 2006 Aug;24(8):1499-505
16877951
J Hypertens. 2010 Jun;28(6):1273-80
20216085
Science. 2006 Aug 25;313(5790):1137-40
16931765
Acta Pathol Jpn. 1989 Nov;39(11):683-705
2694754
Hypertens Res. 2001 Jul;24(4):453-7
11510759
Am Heart J. 2004 Jun;147(6):1024-32
15199351
Adv Exp Med Biol. 2000;483:1-25
11787586
Life Sci. 2002 Apr 5;70(20):2355-66
12150200
Hypertension. 1995 Feb;25(2):155-61
7843763
Hypertension. 2004 Dec;44(6):897-902
15477382
J Biomed Sci. 2010 Aug 24;17 Suppl 1:S21
20804596
Clin Exp Pharmacol Physiol Suppl. 1995 Dec;22(1):S244-5
9072375
J Hypertens. 2005 Oct;23(10):1831-7
16148606
Adv Exp Med Biol. 2009;643:13-25
19239132
Cardiovasc Res. 2006 Oct 1;72(1):163-74
16901476
J Nutr. 2008 Dec;138(12):2386-91
19022962
Dig Dis Sci. 2006 Dec;51(12):2225-34
17080243
Biochem Pharmacol. 1978;27(23):2689-92
728224
Hypertension. 2009 Jun;53(6):1017-22
19398656
Circulation. 2003 Jan 28;107(3):410-5
12551864
Arch Intern Med. 2005 Nov 28;165(21):2479-84
16314544
Clin Exp Pharmacol Physiol Suppl. 1992;20:43-52
1446409
J Cardiovasc Risk. 2000 Feb;7(1):31-5
10785871
Clin Exp Pharmacol Physiol. 1993 Sep;20(9):587-93
8222339
J Hypertens. 1997 Jan;15(1):3-17
9050965
Adv Exp Med Biol. 1996;403:615-22
8915402
Pharmacology. 1996 May;52(5):303-13
8807674
N Engl J Med. 2002 Nov 14;347(20):1557-65
12432042
Neurochem Res. 2004 Jan;29(1):117-26
14992270
J Hypertens. 2001 Mar;19(3 Pt 2):535-8
11327626
J Hypertens. 2002 Nov;20(11):2269-74
12409966
Am J Ther. 2007 Jul-Aug;14(4):375-85
17667214
Clin Exp Hypertens. 1994 May;16(3):317-26
8038757
Jpn Circ J. 1963 Mar;27:282-93
13939773
Diabetes. 1984 Jun;33(6):596-603
6373464
J Cardiovasc Pharmacol. 1987;10 Suppl 1:S165-8
2442511
Jpn Circ J. 1991 May;55(5):500-8
2062001